Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz2. fázis

Conditioning SCID Infants Diagnosed Early

A legfontosabb adatok

Ki végzi
Center for International Blood and Marrow Transplant Research
Hol
Ann Arbor, Atlanta, Aurora, Birmingham, Boston, Charlotte, Chicago, Cincinnati, Dallas, Durham, Gainesville, Grand Rapids, Hackensack, Kansas City, Los Angeles, Madison, Miami, Milwaukee, Minneapolis, Nashville, New Orleans, New York, Omaha, Philadelphia, Phoenix, Pittsburgh, Portland, Queens, Salt Lake City, San Diego, San Francisco, Seattle, St. Petersburg és Washington D.C. (Egyesült Államok)Mind a 35 helyszín megnézéseMég 1 másik országban, 3 helyszínen
Azonosító
Állapot
Fut, nem toboroz
Fázis
2. fázis
Résztvevők
56 fő, tervezett
Kezdés
2018. okt. 22.
Várható befejezés
2028. dec. 1.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • Busulfan
  • Cell processing for TCRαβ+/CD19+ depletion
A regiszteradat frissítve
2026. november 16.

Ki vehet részt

Életkor
0 év – 2 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Infants with SCID, either typical or leaky or Omenn syndrome
  • Typical SCID is defined as either of the following; Absence or very low number of T cells (CD3+ T cells <300/microliter AND no or very low T cell function (<10% of lower limit of normal) as measured by response to phytohemagglutinin OR; Presence of maternally derived T cells
  • Leaky SCID is defined as the following; Absence of maternally derived T cells; AND either one or both of the following (i, ii): i) <50% of lower limit of normal T cell function as measured by response to PHA OR <30% of lower limit of normal T cell function as measured by response to CD3 ii) Absent or <10% of lower limit of normal proliferative responses to candida and tetanus toxoid antigens (must document post vaccination or exposure for this criterion to apply); AND at least two of the following (i through iii): i) CD3 T cells < 1500/microliter ii) >80% of CD3+ or CD4+ T cells are CD45RO+ AND/OR >80% of CD3+ or CD4+ T cells are CD62L negative AND/OR >50% of CD3+ or CD4+ T cells express HLA-DR (at < 4 years of age) AND/OR are oligoclonal T iii) Low TRECs and/or the percentage of CD4+/45RA+/CD31+ or CD4+/45RA+/CD62L+ cells is below the lower level of normal
  • Omenn syndrome • Generalized skin rash; Maternal lymphocytes tested for and not detected; >80% of CD3+ or CD4+ T cells are CD45RO+ AND/OR >80% of CD3+ or CD4+ T cells are CD62L negative AND/OR >50% of CD3+ or CD4+ T cells express HLA-DR (<2 years of age); Absent or low (up to 30% lower limit of normal (LLN)) T cell proliferation to antigens (Candida, tetanus) to which the patient has been exposed IF: Proliferation to antigen was not performed, but at least 4 of the following 8 supportive criteria, at least one of which must be among those marked with an asterisk (*) below are present, the patient is eligible as Omenn Syndrome; Hepatomegaly; Splenomegaly; Lymphadenopathy; Elevated IgE; Elevated absolute eosinophil count; *Oligoclonal T cells measured by CDR3 length or flow cytometry (upload report); *Proliferation to PHA is reduced to < 50% of lower limit of normal (LLN) or SI < 30; *Low TRECs and/or percentage of CD4+/RA+ CD31+ or CD4+/RA+ CD62L+ cells below the lower level of normal; Documented mutation in one of the following SCID-related genes
  • Cytokine receptor defects (IL2RG, JAK3) b. T cell receptor rearrangement defects (RAG1, RAG2) 3. No available genotypically matched related donor (sibling) 4. Availability of a suitable donor and graft source
  • Haploidentical related mobilized peripheral blood cells
  • 9/10 or 10/10 allele matched (HLA-A, -B, -C, -DRB1, -DQB1) volunteer unrelated donor mobilized peripheral blood cells 5. Age 0 to 2 years at enrollment; Note: to ensure appropriate hepatic metabolism, age at time of busulfan start:; For IL2RG/JAK3: 8 weeks For RAG1/RAG2: 12 weeks
  • Adequate organ function defined as:
  • Cardiac:; Left ventricular ejection fraction (LVEF) at rest ≥ 40% or, shortening fraction (SF) ≥ 26% by echocardiogram
  • Hepatic:; Total bilirubin < 3.0 x the upper limit of normal (ULN) for age (patients who have been diagnosed with Gilbert's Disease are allowed to exceed this limit) and AST and ALT < 5.0 x ULN for age
  • Renal:; GFR estimated by the updated Schwartz formula ≥ 90 mL/min/1.73 m2. If the estimated GFR is < 90 mL/min/1.73 m2, then renal function must be measured by 24-hour creatinine clearance or nuclear GFR, and must be > 50 mL/min/1.73 m2
  • Pulmonary No need for supplemental oxygen and O2 saturation > 92% on room air at sea level (with lower levels allowed at higher elevations per established center standard of care)

Ki nem vehet részt

  • Presence of any serious life-threatening or opportunistic infection at time of enrollment and prior to the initiation of the preparative regimen. Serious infections as defined below that occur after enrollment must be reported immediately to the Study Coordinating Center, and enrollment will be put on hold until the infection resolves. Ideally enrolled subjects will not have had any infection. If patients have experienced infections, these must have resolved by the following definitions:; Bacterial i. Positive culture from a sterile site (e.g. blood, CSF, etc.): Repeat culture(s) from same site must be negative and patient has completed appropriate course of antibacterial therapy (typically at least 10 days); Tissue-based clinical infection (e.g. cellulitis): Complete resolution of clinical signs (e.g. erythema, tenderness, etc.) and patient has completed appropriate course of antibacterial therapy (typically at least 10 days); Pneumonia, organism not identified by bronchoalveolar lavage: Complete resolution of clinical signs (e.g. tachypnea, oxygen requirement, etc.) and patient has completed appropriate course of antibacterial therapy (typically at least 10 days). If possible, radiographic resolution should also be demonstrated; Fungal i. Positive culture from a sterile site (e.g. blood, CSF, etc.): Repeat culture(s) from same site is negative and patient has completed appropriate course of antifungal therapy (typically at least 14 days). The patient may be continued on antifungal prophylaxis following completion of the treatment course; Pneumocystis i. Complete resolution of clinical signs (e.g. tachypnea, oxygen requirement, etc.) and patient has completed appropriate course of therapy (typically at least 21 days). If possible, radiographic resolution should also be demonstrated. The patient may be continued on prophylaxis following completion of the treatment course; Viral i. Viral PCRs from previously documented sites (blood, nasopharynx, CSF) must be re-tested and are negative; If re-sampling a site is not clinically feasible (i.e. BAL fluid): Complete resolution of clinical signs (e.g. tachypnea, oxygen requirement, etc.). If possible, radiographic resolution should also be demonstrated
  • Patients with HIV or HTLV I/II infection will be excluded

Helyszínek itt: Egyesült Államok

Még 1 másik országban, 3 helyszínen

  • The University of MichiganAnn Arbor, Egyesült Államok
  • Children's Healthcare of Atlanta at EglestonAtlanta, Egyesült Államok
  • University of Colorado - Children's HospitalAurora, Egyesült Államok
  • Univeristy of Alabama at BirminghamBirmingham, Egyesült Államok
  • Dana Farber Cancer Institute - PedsBoston, Egyesült Államok
  • Levine Children's HospitalCharlotte, Egyesült Államok
  • Comer Children's Hospital/University of Chicago MedicineChicago, Egyesült Államok
  • Cincinnati Children's Hospital Medical CenterCincinnati, Egyesült Államok
  • Children's Medical Center DallasDallas, Egyesült Államok
  • Duke University Medical Center; Pediatric Blood and Marrow TransplantDurham, Egyesült Államok
  • Shands HealthCare & University of FloridaGainesville, Egyesült Államok
  • Helen DeVos Children'sGrand Rapids, Egyesült Államok
  • Hackensack University Medical CenterHackensack, Egyesült Államok
  • The Children's Mercy Hospitals and ClinicsKansas City, Egyesült Államok
  • Children's Hospital Los AngelesLos Angeles, Egyesült Államok
  • UCLA Center for Health SciencesLos Angeles, Egyesült Államok
  • University of Wisconsin Hospital and ClinicsMadison, Egyesült Államok
  • University of Miami/ Jackson Memorial HospitalMiami, Egyesült Államok
  • Children's Hospital of WisconsinMilwaukee, Egyesült Államok
  • University of Minnesota Blood and Marrow Transplant Program - PediatricsMinneapolis, Egyesült Államok
  • Vanderbilt University Medical CenterNashville, Egyesült Államok
  • Children's Hospital / LSUHSCNew Orleans, Egyesült Államok
  • Morgan Stanley Children's Hospital of New York-Presbyterian - Columbia University Medical CenterNew York, Egyesült Államok
  • Nebraska MedicineOmaha, Egyesült Államok
  • Children's Hospital of PhiladelphiaPhiladelphia, Egyesült Államok
  • Mayo Clinic Arizona and Phoenix Children's HospitalPhoenix, Egyesült Államok
  • Children's Hospital of Pittsburgh of UPMCPittsburgh, Egyesült Államok
  • Oregon Health and Science UniversityPortland, Egyesült Államok
  • Cohen Children's Medical CenterQueens, Egyesült Államok
  • Utah Blood and Marrow Transplant Program-PedsSalt Lake City, Egyesült Államok
  • Rady Children's Hospital - San DiegoSan Diego, Egyesült Államok
  • University of California San Francisco Medical Center - PedsSan Francisco, Egyesült Államok
  • Fred Hutchinson Cancer Center / Seattle Children'sSeattle, Egyesült Államok
  • All Children's HospitalSt. Petersburg, Egyesült Államok
  • Children's National Medical CenterWashington D.C., Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants.

A teljes eredeti leírásKevesebb

The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. The exact regimen depends on the subtype of SCID the patient has. Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is completed, patients will be followed for 3 years. Approximately 9-18 months after the transplant, vaccinations will be administered, and a blood test measuring whether your child's body has responded to the vaccine will be collected.

A vizsgálat 2 csoportja

  • Low Dose BusulfanA vizsgált kezelés

    Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 25-35 mg\*h/L . Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks.

    Kezelés: Busulfan és Cell processing for TCRαβ+/CD19+ depletion

  • Medium Dose BusulfanA vizsgált kezelés

    Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 55-65 mg\*h/L. Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks.

    Kezelés: Busulfan és Cell processing for TCRαβ+/CD19+ depletion

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
A regiszteradat frissítve
2026. november 16.